Liberty Vision

Liberty Vision manufactures specialized ophthalmic brachytherapy devices for the treatment of ocular tumors and benign eye growths. The company's primary product line comprises the LV Y‑90 Disc, a high-purity beta radiation episcleral brachytherapy source, and the iWand® Applicators, a manual radionuclide applicator system designed for precise positioning. Both products are single-use, minimally invasive devices intended for extraocular application. The Y‑90 Discs feature configurable activity levels customized per order, with treatment dwell times measured in minutes rather than days, and decay cycles measured in weeks rather than decades, offering environmental advantages over traditional radiation sources. The iWand® series includes anterior applicators with integrated transparent shielding and posterior applicators with integrated positioning light features to facilitate accurate disc placement. Liberty Vision's technology is grounded in decades of clinical research led by founder and Chief Medical Officer Dr. Paul T. Finger, MD, conducted in collaboration with medical physics and radiation oncology experts. The company focuses on streamlining ophthalmic brachytherapy workflows through purpose-built, single-use components and integrated positioning features. Products are indicated for treating ocular tumors and benign growths in eye care settings, with expanding product offerings including 6mm and 10mm Y‑90 Disc configurations. The company publishes clinical research and maintains active engagement with ophthalmology conferences and institutions establishing ophthalmic brachytherapy programs.